Topoisomerase II-catalyzed DNA transport requires coordination between two distinct reactions: ATP hydrolysis and DNA cleavage/religation. To further understand how these reactions are coupled, inhibition by the clinically used anticancer drug etoposide was studied. The IC 50 for perturbing the DNA cleavage/religation equilibrium is nucleotide-dependent; its value is 6 M in the presence of ATP, 25 M in the presence of a nonhydrolyzable ATP analog, and 45 M in the presence of ADP or no nucleotide. This inhibition was further characterized using steady-state and pre-steady-state ATPase and decatenation assays. Etoposide is a hyperbolic noncompetitive inhibitor of the ATPase activity with a K i (app) of 5.6 M; no inhibition of ATP hydrolysis is seen in the absence of DNA cleavage. In order to determine which steps of the ATPase mechanism etoposide inhibits, presteady-state analysis was performed. These results showed that etoposide does not reduce the rate of binding two ATP, hydrolyzing the first ATP, or releasing the second ADP. Inhibition is therefore associated with the first product release step or hydrolysis of the second ATP, suggesting that DNA religation normally occurs at one of these two steps. Multiple turnover decatenation is inhibited when etoposide is present; however, single turnover decatenation occurs normally. The implications of these results are discussed in terms of their contribution to our current model for the topoisomerase II mechanism.
Topoisomerase II-catalyzed DNA transport requires coordination between two distinct reactions: ATP hydrolysis and DNA cleavage/religation. To further understand how these reactions are coupled, inhibition by the clinically used anticancer drug etoposide was studied. The IC 50 for perturbing the DNA cleavage/religation equilibrium is nucleotide-dependent; its value is 6 M in the presence of ATP, 25 M in the presence of a nonhydrolyzable ATP analog, and 45 M in the presence of ADP or no nucleotide. This inhibition was further characterized using steady-state and pre-steady-state ATPase and decatenation assays. Etoposide is a hyperbolic noncompetitive inhibitor of the ATPase activity with a K i (app) of 5.6 M; no inhibition of ATP hydrolysis is seen in the absence of DNA cleavage. In order to determine which steps of the ATPase mechanism etoposide inhibits, presteady-state analysis was performed. These results showed that etoposide does not reduce the rate of binding two ATP, hydrolyzing the first ATP, or releasing the second ADP. Inhibition is therefore associated with the first product release step or hydrolysis of the second ATP, suggesting that DNA religation normally occurs at one of these two steps. Multiple turnover decatenation is inhibited when etoposide is present; however, single turnover decatenation occurs normally. The implications of these results are discussed in terms of their contribution to our current model for the topoisomerase II mechanism.
Type II DNA topoisomerases are essential and ubiquitous enzymes required for a number of DNA metabolic processes including unlinking of intertwined daughter chromosomes, manipulation of DNA supercoiling, and chromosomal condensation/decondensation (1, 2) . DNA topoisomerase II catalyzes the ATP-dependent transport of one DNA duplex through an enzyme-mediated double-stranded break in a second DNA duplex (reviewed in Ref. 3) . Additionally, these enzymes are the targets of a number of clinically used antibiotic and anticancer drugs (4 -6) . Many of these drugs, including etoposide, act by stabilizing the covalent topoisomerase II-DNA intermediate (reviewed in Ref. 7) . This stabilized enzyme-cleaved DNA complex acts as a cellular poison (6, 8) .
During one topoisomerase II reaction cycle, two ATPs are hydrolyzed, one segment of double-stranded DNA is cleaved and religated, and a second segment of DNA is transported through the transient break in the first. In order to understand the mechanism of this enzyme, it is essential to understand each of these reactions and how they are coordinated. Much has already been learned about the individual reactions. In the presence of DNA, the homodimeric enzyme rapidly binds two ATP (9) , causing the amino-terminal ATPase domains to dimerize (10 -12) . One of the two ATPs is rapidly hydrolyzed (13) . The ADP produced is slowly released, representing the slowest or rate-determining step in the ATPase reaction; only after that first ADP is released does the enzyme hydrolyze the second ATP (13) . The segment of DNA cleaved and religated by the enzyme has been called the gate or "G" segment (14) . Topoisomerase II cleaves and religates both strands of the G segment using a pair of active site tyrosines, one in each monomer of the dimer (15) . The cleavage reaction results in a four-base staggered break in the DNA, with an enzyme monomer covalently attached to each 5Ј-phosphate (16, 17) . Religation is essentially the reverse reaction of cleavage, where the 3Ј-hydroxyls attack the phosphotyrosyl linkages. After the enzyme cleaves and separates the G segment, it passes a second segment of DNA, the transport or "T" segment, through the break before it religates the G segment. The rate constant for T segment transport indicates that this step occurs after hydrolysis of the first ATP (18) . Etoposide is a widely used drug for the treatment of several neoplasias, including testicular and small cell lung cancers (19) . The best evidence that topoisomerase II is the cellular target for this drug comes from studying the heterologous expression of wild type and drug-resistant mutant topoisomerase II alleles in yeast (20, 21) . Etoposide functions by perturbing the DNA cleavage/religation equilibrium of topoisomerase II (7, 8) . In the absence of drug, this equilibrium strongly favors religation such that at any given instant only a small fraction of the enzyme is covalently attached to cleaved DNA (22) . When etoposide binds the enzyme-DNA complex, it inhibits the rate of G segment religation (23, 24) . Therefore, a substantially larger fraction of the enzyme remains covalently attached to cleaved DNA in the presence of this drug.
Given etoposide's role in inhibiting topoisomerase II from religating the G DNA segment, it is a useful probe for analyzing the coordination among the various reactions in this enzyme's mechanism. In a previous study, the effects of inhibiting DNA cleavage on G and T segment binding and ATPase activity was analyzed using cleavage-deficient mutants of yeast topoisomerase II (26) . In the present study, the effects of preventing religation on the ATPase reaction cycle and DNA transport are investigated. Although inhibition of topoisomerase II by etoposide has been previously studied, the introduction of rapid kinetic techniques for studying this enzyme and the surprising mechanistic data resulting from their use (9, 13, 18, 26) warrant a revisit to this inhibitor. SO . Sheared salmon sperm DNA used for the ATPase assays was prepared as described previously (9) . Kinetoplast DNA was purified from Crithidia fasciculata as described (25) . Wild type and Y782F mutant Saccharomyces cerevisiae topoisomerase II enzymes were expressed and purified as before (26) . The concentrations of topoisomerase II given are for the dimer. The reaction buffer used throughout contained 50 mM HEPES-KOH (pH 7.5), 150 mM KOAc, and 10 mM Mg(OAc) 2 . The agarose gel loading buffer after final dilution contained 10% glycerol, 0.1% bromphenol blue, 0.1% xylene cyanol, and 10 mM EDTA. All of the gels were run in TBE (89 mM Tris borate, 2 mM EDTA).
Topoisomerase II DNA Cleavage Assays-Each cleavage reaction contained 50 nM topoisomerase II and 25 nM supercoiled plasmid (pBluescript KS ϩ ) in reaction buffer plus 250 g/ml bovine serum albumin and etoposide. Me 2 SO (1% final concentration) was included in the reactions lacking etoposide. In one set of reactions an ATP-regenerating system consisting of 2 mM phospho(enol)pyruvate and 6.4 units/ml of pyruvate kinase was included. The reactions were held at 30°C for 15 min before being quenched with 0.5% SDS. Proteinase K (500 g/l) was added and incubated for 1 h at 45°C to digest topoisomerase II from the DNA breaks before adding gel loading buffer. Samples were electrophoresed in a 0.8% agarose gel at 10 V/cm for 4 h in TBE containing 5 g/ml ethidium bromide. Gels were destained in water and photographed over a UV transilluminator using the Eagle Eye II still photo system (Stratagene). Fluorescent bands were quantified using Scion Image Quant software (Scion Corp.). To determine the concentration required for 50% of the maximal cleavage (IC 50 ), linearized DNA was quantified from reactions containing nine or 10 different etoposide concentrations (0.5-700 M). A 12-kilobase pair linear DNA loading control was also quantified for each reaction and used to adjust for any loading differences. These data were then plotted and fit to a simple cleavage/religation equilibrium (relative cleavage ϭ [I]/([I] ϩ IC 50 ), where I is etoposide) to determine the IC 50 using KaleidaGraph 3.0.
Steady-state ATPase Assays with Etoposide-Steady-state inhibition of ATP hydrolysis by topoisomerase II was determined using a coupled spectrophotometric assay involving pyruvate kinase, phospho(enol-)pyruvate, lactate dehydrogenase, and NADH as described previously (27) . Purified and sheared salmon sperm DNA was used at a ratio of 200 base pairs/enzyme dimer. Reactions were performed at 30°C in reaction buffer at six different ATP concentrations (50 M to 1.5 mM) and seven different etoposide concentrations (0.5-150 M) or 1% Me 2 SO. Control reactions showed that neither etoposide nor Me 2 SO inhibited the coupling system. The data were fit using Grafit (Erithicus Software).
Pre-steady-state ATPase Assays-Rapid chemical quench and pulsechase experiments were performed essentially as described previously (9, 26) except that either etoposide (150 M final concentration) or Me 2 SO (1% final concentration) was included in the topoisomerase II/DNA reaction mix. Briefly, topoisomerase II bound to DNA was rapidly mixed with [␣-32 P]ATP (0.01 Ci/l) in reaction buffer using the rapid mix chemical quench RQF-3 from KinTeK (28) . The final topoisomerase II dimer and DNA concentrations were 9.9 M and 2 mM base pairs, respectively. The final labeled ATP concentration was 350 M. The enzyme, DNA, and etoposide were allowed to incubate for at least 10 min before reacting with labeled ATP for between 20 ms and 2.0 s. The concentration of [␣-
32 P]ADP produced at each time was determined by TLC analysis; the data were quantified as described previously (9) and fit to a single exponential equation with a linear term, A(1-e ϪBt ) ϩ Ct using KaleidaGraph 3.0. The A value is the burst amplitude, B is the burst rate constant, and C is the steady-state term. Although only a single set of data is shown, similar results were obtained upon repeating the experiment.
Decatenation Assays-For multiple turnover assays, topoisomerase II (20 nM final concentration) was mixed with kinetoplast DNA (20 g/ml final concentration) in reaction buffer plus 250 g/ml bovine serum albumin. Etoposide (150 M final concentration) or Me 2 SO (1% final concentration) was added to each set of reactions and allowed to incubate for 5 min at 30°C. After this preincubation, an aliquot was removed prior to the ATP addition (1 mM final concentration). Aliquots (20 l) were removed at the indicated time points and quenched with 50 mM EDTA. After 2 min, an equal volume of loading buffer plus 0.5% SDS was added prior to electrophoresis in an 0.8% agarose gel at 10 V/cm for 4 h. Gels were stained in ethidium bromide, destained in water, and photographed over a UV transilluminator.
Single turnover DNA decatenation experiments were performed using the rapid quench apparatus, as described previously (18) . The reaction time courses were each performed twice.
RESULTS
Etoposide-altered DNA Cleavage/Religation EquilibriumEtoposide is well known to perturb the DNA cleavage/religation equilibrium of topoisomerase II, primarily by inhibiting the rates of religation (23, 24) . As a first step in analyzing the effects of perturbing this equilibrium on the overall reaction mechanism, DNA cleavage assays using yeast topoisomerase II in its optimized reaction buffer (9) were performed. As the concentration of etoposide is increased, enzyme-mediated double-stranded breaks in DNA accumulate, an example of which is shown Fig. 1A . Similar cleavage experiments were performed in the presence of 1 mM ATP, 1 mM ATP with a regenerating system, 1 mM AMP-PNP, 1 mM ADP, or no added nucleotide. In each case, only the conversion of supercoiled DNA to linear was quantified, as shown in Fig. 1B ; inclusion of the nicked DNA did not alter the calculated IC 50 values. In the presence of ATP, the IC 50 for etoposide was 6 Ϯ 1 M, regardless of whether a regenerating system was present; for clarity, only the data from experiments lacking the regenerating system are shown. In the presence of AMP-PNP, the IC 50 increased to 25 Ϯ 4 M. In the presence of ADP or absence of nucleotide, the IC 50 again increased to 45 Ϯ 4 M; only the data from experiments in the absence of nucleotide are shown in the figure. It is clear from these results that the nucleotide bound state of topoisomerase II affects its interaction with etoposide. The experiments described below probe the effect of etoposide on the ATPase and decatenation activities of topoisomerase II.
Steady-state ATPase Inhibition-Steady-state ATPase studies were performed to determine the relationship between etoposide-inhibited religation and multiple turnover ATPase activity. Steady-state parameters for the ATPase reaction were determined at seven etoposide concentrations, ranging from both above and below the IC 50 . The double reciprocal plot of these data is shown in Fig. 2A . Analysis of the data immediately suggested that it was a noncompetitive type of inhibition, in which the K m (app) values remain constant and the V max -(app) values are reduced; equations describing other modes of inhibition did not fit the data. When the data were analyzed as initial velocity versus inhibitor concentration, it became apparent that etoposide is not a standard noncompetitive inhibitor (Fig. 2B) . For a traditional noncompetitive inhibitor, as the inhibitor concentration is increased, the initial velocity will approach 0. However, for etoposide the initial velocities plateau at values greater than 0. In other words, even when very high concentrations of etoposide are present, topoisomerase II continues to hydrolyze ATP, albeit at an inhibited rate. Therefore, etoposide shows all of the characteristics of a hyperbolic, noncompetitive inhibitor (29) , the mechanism of which is shown in Scheme 1, where E is topoisomerase II, I is etoposide, S is ATP, and P is ADP/P i .
The data in Fig. 1A are shown globally fit to the equation for hyperbolic, noncompetitive inhibition as follows.
The values for K m , k cat , K i (app), and ␤k cat determined from this fit are 143 M, 4.6 s Ϫ1 , 5.6 M, and 1.3 s
Ϫ1
, respectively. In order to show that the ATPase inhibition was directly related to etoposide's effect on the DNA cleavage/religation equilibrium, similar studies were done in the absence of DNA or with a DNA cleavage mutant, Y782F, bound to DNA (26) . Results of the analysis under these conditions, with and without 150 M etoposide, are shown in Table I . In neither case does the k cat or k cat /K m change in the presence of etoposide. Even when the etoposide concentration was increased to 250 M, there was no detectable inhibition (data not shown). Taken together, these data indicate that etoposide only inhibits the ATPase activity of topoisomerase II if the enzyme is bound to, and capable of cleaving, DNA.
Pre-steady-state ATPase Inhibition-Although the steadystate ATPase assays showed that one or more steps of the reaction mechanism are perturbed by etoposide, they do not indicate which step(s). Previous pre-steady-state analysis showed that topoisomerase II hydrolyzes two ATP by an unusual sequential pathway (13) , as illustrated in Scheme 2, where E 2 represents dimeric topoisomerase II bound to DNA, S represents ATP, P represents ADP-P i , and E 2 S* represents a state of topoisomerase II bound to a single ATP that differs from E 2 S.
Since pre-steady-state experiments allow these individual steps to be probed, the effect of etoposide on the ATPase reaction was studied using these techniques. Two separate types of pre-steady-state, rapid quench experiments have been used to study the topoisomerase II-ATPase reaction cycle: pulse chase and chemical quench. In a pulse-chase reaction, topoisomerase bound to DNA is rapidly mixed with labeled ATP. At the indicated time points, a large excess of unlabeled ATP is added, and the reaction is allowed to continue for several turnovers before being chemically quenched. In the pulse-chase experiments, the rate of the burst phase reflects the rate of binding two labeled ATPs, while the burst amplitude indicates the concentration of rapidly bound labeled ATP that is hydrolyzed. 
SCHEME 1

Inhibition of Topoisomerase II by Etoposide
The data after the burst represent the steady-state ATPase rate. Pulse-chase data are shown as open symbols in Fig. 3 for reactions both with (squares) and without 150 M etoposide (circles). The final topoisomerase II concentration in these assays was 9.9 M dimer. The pulse-chase burst rate constants calculated from these data are 80 and 90 s Ϫ1 , in the absence and presence of etoposide, respectively. These values represent lower estimates of the apparent first order binding rate constants, since the majority of the labeled ATP is bound by the first time point. However, a significant reduction in ATP binding rate by etoposide would have been detected in this pulsechase experiment. The pulse-chase burst amplitudes are similar to each other (20 Ϯ 1 and 18 Ϯ 1 M, in the absence and presence of etoposide, respectively) and to the ATP active site concentration present (19.8 M) . These values indicate that the topoisomerase II dimer binds two ATPs and hydrolyzes them both before either can dissociate, regardless of whether etoposide is bound. Etoposide reduces the steady-state rate 3-fold, similar to what was shown in the above steady-state assays.
In a chemical quench experiment, the topoisomerase bound to DNA is rapidly mixed with labeled ATP and quenched at the indicated time points. The chemical quench burst amplitude indicates the concentration of ATP that is hydrolyzed before the rate-determining step in the reaction, while the burst rate constant reflects the rate at which that ATP is hydrolyzed. The data after the burst again represent the steady-state rate. The chemical quench burst amplitudes in the absence and presence of etoposide are 9.4 Ϯ 0.9 and 9.5 Ϯ 0.8 M, respectively. These values are similar to the enzyme dimer concentration (9.9 M), or half the ATPase active site concentration present. As was previously shown, this indicates that only one of the two bound ATP are hydrolyzed before the rate-determining step in the ATPase cycle. The chemical quench burst rate constants are 20 Ϯ 4 and 22 Ϯ 4 s Ϫ1 , again in the absence and presence of etoposide, respectively. These similar values indicate that etoposide does not reduce the rate at which topoisomerase II hydrolyzes the first ATP. They also indicate that the ratedetermining step of the ATPase reaction in the presence of etoposide still occurs after hydrolysis of the first ATP and before products of the second hydrolysis can be detected (i.e. it is represented by either k 4 or k 5 of Scheme 2). As was seen in the pulse-chase data, in the presence of etoposide the steadystate phase of the chemical quench data is again 3-fold slower.
Taken together, the pulse-chase and chemical quench data indicate that etoposide does not significantly inhibit any of the first three steps of the ATPase cycle (see Scheme 2), which include binding of the two ATP and the rapid hydrolysis of the first. Additionally, etoposide does not significantly slow the release of the second ADP (represented by k 6 in Scheme 2) because the rate-determining step must remain either that represented by k 4 or k 5 , as demonstrated by the unchanged chemical quench burst. Therefore, etoposide inhibits the ATPase activity of topoisomerase II by either reducing the rate of release of the first ADP (k 4 ), or by reducing the rate of the second ATP hydrolysis (k 5 ) sufficiently to make it the ratedetermining step in the inhibited turnover.
Effect of Etoposide on DNA Transport by Topoisomerase IIPrevious results on the inhibition of DNA transport by etoposide are confusing, because transport, as measured by decatenation or unknotting, was inhibited in the presence of ATP (8, 30, 31) but not in the presence of a nonhydrolyzable ATP analog (32) . To clarify how inhibiting G segment religation by etoposide affects ATP hydrolysis-driven DNA transport, the rates of multiple turnover and single turnover decatenation were studied.
Topoisomerase II-catalyzed multiple turnover decatenation was analyzed using kinetoplast DNA. Kinetoplast DNA consists of approximately 5,000 multiply linked 2.5-kilobase pair circles that cannot enter an agarose gel. After many rounds of reaction with topoisomerase II, the individual circles are freed and migrate in a gel as expected for a DNA circle of this size. Topoisomerase II-catalyzed kinetoplast DNA decatenation reactions were performed in the absence and presence of 150 M etoposide. At the indicated time points, aliquots of the reactions were quenched and analyzed by agarose gel electrophoresis, as shown in Fig. 4 . The presence of etoposide reduces the multiple turnover decatenation rate between 4-and 10-fold. DNA circles should not have been released simply by quenching the topoisomerase-DNA cleavage complexes, because the manner in which these reactions were stopped (the addition of EDTA prior to SDS) is known to force DNA religation, even in the presence of etoposide (23) . These results show that etoposide inhibits kinetoplast DNA decatenation to a similar extent that it inhibits the steady-state ATPase activity.
In order to interpret etoposide's inhibition of the multiple turnover kinetoplast DNA decatenation results, rapid quench, single turnover decatenation experiments were done. In the single turnover experiments, a 2:1 molar excess of topoisomerase II was prebound to two singly linked 2.1-kilobase pair DNA circles. The enzyme and DNA were rapidly mixed with ATP and quenched at the desired time points, using a rapid quench apparatus. The substrates and products of the reaction were then separated by agarose gel electrophoresis. Reaction time courses in the absence and presence of saturating etoposide (150 M) are shown in Fig. 5, A and B , respectively. The substrate band does not appear to significantly decrease with time because a remnant of the reaction used to generate the single catenanes co-migrates with the substrate. Fig. 5C shows the quantitation of these data. By fitting these data to a single exponential equation, the decatenation rate constants in the presence and absence of etoposide were both found to be 8 Ϯ 1 s Ϫ1 . In the presence of etoposide, a small amount of free circle is seen before the addition of ATP. This amount of ATP-independent free circle does not increase with time and is apparently released when the topoisomerase covalently linked to one DNA circle is denatured. This small amount of background free circle does not significantly affect the decatenation rate in the presence of etoposide. Therefore, within a single turnover, etoposide does not alter the rate of decatenation. This result, in conjunction with the kinetoplast DNA decatenation result, indicates that etoposide inhibits decatenation after the first DNA transport event.
DISCUSSION DNA topoisomerase II must couple two different chemical reactions, DNA cleavage/religation and ATP hydrolysis, in order to catalyze the transport of one DNA segment through a break in another. This coupling was studied from two different perspectives using the cleaved complex-stabilizing drug etoposide. First, the IC 50 for stabilization of yeast topoisomerase II in the cleaved complex was shown to be nucleotide-dependent; the IC 50 is lowest in the presence of ATP and increases approximately 8-fold in the absence of nucleotide or the presence of ADP. Interestingly, under identical conditions, the IC 50 is 4-fold higher in the presence of a nonhydrolyzable ATP analog compared with ATP. Second, the effects of etoposide on the ATPase and DNA transport activities of topoisomerase II were investigated. The drug was found to inhibit both steady-state activities to similar extents, 3-4-fold for the ATPase and 4 -10-fold for the decatenation. However, etoposide inhibits late within the first turnover, after ATP binding, hydrolysis of the first ATP, and transport of the T segment through the G segment have been completed.
These results are the first comprehensive kinetic characterization of the effects of etoposide on the topoisomerase II reaction cycle. Previous studies have provided evidence that etoposide directly inhibits the rate at which topoisomerase II religates DNA (23, 24) . The reported effects of etoposide on the ATPase activity of type II topoisomerases have been contradictory; the drug was shown to have no effect on the ATPase activity of the Drosophila enzyme (33), while it dramatically inhibited human topoisomerase II␣ ATPase activity (34) . In the present study, etoposide is shown to be a hyperbolic, noncompetitive inhibitor of the ATPase activity of yeast topoisomerase II bound to DNA. In other words, etoposide and ATP do not compete for binding to topoisomerase II (the K m values for ATP are identical in the presence and absence of etoposide), and even in the presence of saturating etoposide, the enzyme continues to hydrolyze ATP, albeit at a reduced rate. The K i (app) for inhibiting the ATPase activity is the same as the IC 50 for DNA cleavage in the presence of ATP. The fact that these two values, measured under identical reaction conditions but by two different assays, are equal suggests that they represent the The results of previous studies showed that etoposide inhibited DNA transport as measured by multiple turnover assays using ATP (8, 30, 31) but did not inhibit DNA transport in assays using nonhydrolyzable ATP analogs (32) . The present results from steady-state and pre-steady-state DNA decatenation experiments agree with and help to explain the past findings. Etoposide inhibits steady-state decatenation to a similar extent that it inhibits the steady-state ATPase. Since multiple turnover decatenation is dependent upon the ATPase reaction cycle, it must be inhibited to at least the same extent as the ATPase activity. Single turnover decatenation as measured by rapid quench kinetics is uninhibited by etoposide. Since the pre-steady-state ATPase assays showed that etoposide inhibits . Although the data shown in A and B were from a single integration, the rate constant of 8 Ϯ 1 s Ϫ1 was determined for reactions both with and without etoposide by analyzing these data on two separate gels using two different integrations.
the ATPase cycle some time after hydrolysis of the first ATP and DNA transport has been shown to occur immediately after the first ATP hydrolysis (18), it is not surprising that the drug does not inhibit single turnover decatenation. With a nonhydrolyzable ATP analog, topoisomerase II promotes DNA transport much more slowly, regardless of whether the drug is present, than with ATP (18) .
The coupling of the ATPase and DNA cleavage/religation reactions by topoisomerase II was previously studied from the opposite perspective: analyzing the activity of mutants that cannot cleave DNA (26) . These studies showed that the failure to cleave the G segment does not perturb the enzyme's affinity for the G segment or the rates of binding two ATPs. However, in the absence of G segment cleavage, the T segment of DNA is not stably bound by the enzyme, and the rate at which the enzyme hydrolyzes the first ATP is reduced 3-4-fold.
A proposed model for the mechanism of topoisomerase II, based on the present and previously published pre-steady-state ATPase and decatenation results (9, 13, 18, 26) , crystal structures of several different type II topoisomerase fragments (36 -39) , and biochemical experiments from many laboratories (reviewed in Ref. 3) , is presented in Fig. 6 . While a detailed description of the model is presented elsewhere (18) , a brief description of the steps is as follows. 1) The homodimeric enzyme binds the G segment of DNA in the cleavage active site.
2) The binding of two ATP dimerizes the amino-terminal domains (10 -12) , entrapping a T segment of DNA. Since the T segment is not found trapped in the absence of G segment cleavage, the G segment is presumed to be cleaved by this step in the mechanism (26). 3) One of the two ATPs is stochastically hydrolyzed. The rate of this hydrolysis step is reduced if the G segment cannot be cleaved (26) . This reduction may be a result of the T segment not being bound in the absence of G segment cleavage. 4) transport of the T segment through the G segment occurs after the first ATP hydrolysis and is potentially triggered by release of the inorganic phosphate (P i ) formed (18) . It is presently unclear what protein and DNA conformational changes next occur, coupled to the rate-determining release of the first ADP, hydrolysis of the second ATP, and release of the final products (13) . However, it is now known that etoposide inhibits the rates of either the first ADP release or the hydrolysis of the second ATP. Since it is doubtful that etoposide directly perturbs events in the ATPase active site, it most likely acts by altering protein conformational changes associated with this latter part of the ATPase cycle. Since the direct effect of etoposide on topoisomerase II is through inhibiting G segment religation, we propose that the G segment must be religated for these latter steps in the mechanism to optimally occur.
Although several aspects of this model are hypothetical, such as the symmetric conformational change that the enzyme is shown to undergo upon release of the first P i , it does help to explain several of the results described above. Since etoposide only inhibits events late in the ATPase reaction cycle of topoisomerase II, the model shows why the drug would inhibit multiple turnover DNA transport but not the first DNA transport event. The different IC 50 values for the different nucleotide-bound states of the enzyme can also be explained by this model. Since the rate-determining step in the ATPase cycle is release of the first ADP, at any given instant when the enzyme is present with ATP and DNA, the largest fraction of the enzyme will be bound to one ADP and one ATP. We propose that this conformation of the enzyme is different from the predominant conformation that exists when the enzyme is bound to a nonhydrolyzable ATP analog or to ADP alone or is free of nucleotide. Therefore, the different IC 50 values may reflect differences in affinity of etoposide for the different conformations of the enzyme-DNA complex. Previously reported IC 50 values of etoposide for type II topoisomerases from a variety of organisms have ranged from 5 to 20 M in the presence of a nonhydrolyzable ATP analog and from 15 to 70 M in its absence (7, 23, 24, 40, 41) . These previous results first suggested that the nucleotide bound state of topoisomerase II affected its affinity for etoposide. The present results extend these findings by including assays with ATP and ADP.
Etoposide is a very effective drug for treating several forms of cancer, but it also has a dangerous side. A small fraction of patients treated with etoposide develop therapy-related leukemia, most often associated with particular chromosome translocations (42, 43) . There is mounting evidence that inhibition of the topoisomerase II reaction cycle by etoposide may play a role in causing the translocations (reviewed in Ref. 42) . Now that we have a better idea where in the reaction cycle etoposide perturbs the topoisomerase, it may become clear how the inhibited form of this enzyme could participate in chromosomal translocations.
